CytomX Therapeutics, Inc. - Common Stock (CTMX)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- Trading 313% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 2/9 — signs of financial weakness
- ROE of 15.0% — good return on equity
- Revenue declining 45% annually
CytomX Therapeutics, Inc. - Common Stock (CTMX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $752 million . Key value metrics: P/E ratio 50.6, P/B ratio 7.60, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CytomX Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
CytomX Therapeutics, Inc. - Common Stock (CTMX) is currently trading 313% above its Graham Number of $1.07, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 50.6x.
On financial health, CTMX shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and solid return on equity of 15.0% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.47.
StockPik's composite Value Score for CTMX is 30/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CTMX shows revenue declining at 45% year-over-year, with earnings declining at 154%.